Cognitive Impairment Amongst Older Adults With Heart Failure: A Global Pooled Meta-Analysis

Maya Asami Takagi1, Adil Sarvar Mohammed2, Umera Yasmeen3

  • 1Department of Internal Medicine, University of California Davis, Sacramento, CA, USA.

Insights

Approximately 44% of older adults with heart failure (HF) experience cognitive impairment (CI). This highlights a significant global health issue, underscoring the need for routine cognitive screening in this population.

Area of Science:

  • Gerontology
  • Cardiology
  • Neurology

Background:

  • Cognitive impairment (CI) is a frequent comorbidity in older adults with heart failure (HF).
  • CI in HF patients is linked to poorer self-care, medication adherence, and clinical outcomes.
  • Prevalence estimates for CI in HF vary due to differing study methodologies and populations.

Purpose of the Study:

  • To estimate the global prevalence of cognitive impairment in older adults with heart failure.
  • To identify sources of variability in reported CI prevalence across studies.

Main Methods:

  • A systematic review and meta-analysis adhering to PRISMA guidelines.
  • Searches of PubMed, Scopus, and Google Scholar databases up to October 2024.
  • Inclusion of observational studies on adults aged ≥65 with diagnosed HF and validated cognitive assessments.
  • Pooled prevalence calculation using a random-effects model; heterogeneity assessed with I² statistic.

Main Results:

  • Twenty-five studies involving 12,112 older adults with HF were analyzed.
  • The pooled prevalence of CI was 43.5% (95% CI: 35.2%-51.9%), with substantial heterogeneity (I²=98.6%).
  • Prevalence varied by region (US: 50.9%, Asia: 46.5%, Europe: 35.0%) and age (≥80 years: 48.6% vs. 70-79 years: 38.9%).

Conclusions:

  • Nearly 44% of older adults with HF suffer from cognitive impairment, indicating a significant global health burden.
  • Routine cognitive screening is recommended for older HF patients to inform clinical decisions and enhance outcomes.
  • Future research should focus on longitudinal cognitive changes and interventions targeting both cognitive and cardiovascular health.
Abstract

Related Concept Videos

Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...